Laurie H. Sehn

Jan 30, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCCSubcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCCDr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCCAdjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

Jan 23, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon CancerctDNA Is Predictive of DFS, Offers Prognostic Tool in CRCFrontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRCDr Li on the Use of ADG126 With Pembrolizumab in MSS CRC

Jan 23, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Sequencing Immunotherapy in the Third-line and Beyond Setting for FLPeter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jan 16, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FLA panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Jan 16, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Zanubrutinib as Third-Line and Beyond Therapy for FLLaurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.